Sandoz Ibandronate 2mg/2ml, 6mg/6ml Injection
PDF Leaflet Revision Date: 10 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of tumour-induced hypercalcaemia and prevention of skeletal complications in breast cancer with bone metastases.
Dosage (summary)
6 mg IV every 3-4 weeks; adjust based on severity of hypercalcaemia.
Special Populations
- Renal impairment
- Hepatic impairment
- Children under 18
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to lack of clinical experience.
Key Drug Interactions
- Aminoglycosides may lower serum calcium
- Do not mix with calcium-containing solutions
Contraindications
- Hypersensitivity to ibandronate
- Pregnancy
- Lactation
- Renal function impairment
- Hepatic impairment
Common side effects
- Infection
- Hypocalcaemia
- Headache
- Dizziness
- Diarrhoea
Counselling Points
- Ensure adequate hydration before infusion
- Monitor for signs of hypocalcaemia
- Dental evaluation recommended before treatment
Serious warnings
- Monitor renal function and electrolytes
- Risk of osteonecrosis of the jaw
- Avoid overhydration in cardiac failure
Important Disclaimer
The Sandoz Ibandronate 2mg/2ml, 6mg/6ml Injection professional information leaflet below is the property of Oethmaan Biosims and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
